Last checked at 8 Apr 2024 12:19
Schroders Capital Global Innovation (INOV)
08/04/2024
Results analysis from Kepler Trust Intelligence
Schroders Capital Global Innovation (INOV) has released its financial results for the year ending 31/12/2023. Over the year, the trust saw its NAV per share decrease by 11.2% on a total return basis, which compares to an average total return of -4.8% for the AIC Growth Capital sector.
Whilst the overall returns were negative, the final quarter of 2023 saw a recovery driven by positive developments in Autolus Therapeutics. Detractors primarily came from the public equity holdings.
The managers have continued to reprofile the trust including the disposal of legacy holdings, adding companies under the new strategy and progress existing holdings towards profitability. There were six new investments in private companies evenly split across the life sciences, venture and growth strategies.
The managers made four exits as well as notable reductions in two more. This activity raised c. £32.8m of which £22.8m was allocated to six new holdings and c. £7m to buybacks.
The board have committed to significant share buy backs with a goal to buy back at least 5% of the shares each year. The discount narrowed by nearly four percentage points to 42.1% at year end.
Chair Tim Edwards believes the final quarter represents the beginning of recovery, stating "The increase in net asset value in the last quarter of the year and the positive news flow … both indicate that momentum is beginning to turn in favour of growth in the new investments in the portfolio".
Kepler View
Tim Creed and Harry Raikes, co-managers of Schroders Capital Global Innovation (INOV), have continued the journey of transitioning the portfolio to predominantly private equity. This will then consist of companies mostly in the tech and healthcare industries and split across three strategies: venture, growth and life-sciences.
The managers have three main goals: reducing legacy holdings, developing the existing portfolio, and making investments that meet the new strategy. The first of these has resulted in four disposals, and two partial sell downs in the year. There have been six new positions in the period, split equally across the venture, growth and life-sciences strategies, all of which were unquoted companies. This activity has tilted the portfolio towards the goal of being predominantly a private equity vehicle.
The development of the existing portfolio has seen a focus on profitability and cash runway. Nearly 30% of portfolio companies were profitable, with another c. 32% having enough cash for two years of operations. This has arguably gone some way to de-risking the portfolio. Financing has become more challenging, therefore this has helped to mitigate risks in our opinion.
NAV over the year was negative, though the positive last quarter arguably reflects a turning point. This was largely driven by Autolus Therapeutics, but since the period end, portfolio holding Carmot Therapeutics was also taken over adding 2.6% to NAV. We believe these holdings demonstrate the upside potential of the portfolio.
Whilst the trust has seen some challenging periods, the managers argue that the new strategy is beginning to deliver on its potential. However, the discount remains wide at 42.1% despite the significant share buy backs. We think that this discount looks interesting, especially considering the buybacks, whilst the NAV could offer upside potential from further growth and corporate activity.
CLICK HERE TO READ THE FULL REPORT Visit Kepler Trust Intelligence for more high quality independent investment trust research.
Important information
This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.
Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.
The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.
The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.
This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.
Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.
PLEASE SEE ALSO OUR TERMS AND CONDITIONS
Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.